momelotinib Ojjaara
Selected indexed studies
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. (J Clin Oncol, 2017) [PMID:28930494]
- Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. (Lancet, 2023) [PMID:36709073]
- Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. (Am J Hematol, 2023) [PMID:36680511]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. (2017) pubmed
- Momelotinib. (2006) pubmed
- Momelotinib. (2012) pubmed
- Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. (2023) pubmed
- Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. (2024) pubmed
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. (2018) pubmed
- Momelotinib: First Approval. (2023) pubmed
- Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. (2023) pubmed
- PMID:40674530 (2025) pubmed
- FDA greenlights momelotinib (Ojjaara) as the exclusive treatment for myelofibrosis patients battling anemia. (2024) pubmed